Olema Pharmaceuticals, Inc. Common Stock OLMA
i
Market datapartial · fetched 2026-11-12T01:34:04.333Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:36:08.473929169Z
FundamentalsAlpha Vantage · unavailable
Olema Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 7.29 | 257.7% | 22.0% | |||
| 35Δ | 7.72 | 224.3% | 17.4% | |||
| 40Δ | ||||||
| 45Δ | 9.21 | 382.1% | 19.7% | |||
| 50Δ | 9.61 | 347.7% | 16.1% | |||
| 55Δ | 10.01 | 313.7% | 12.6% | |||
| 60Δ | 10.74 | 319.6% | 10.8% | |||
| 65Δ | 12.47 | 377.8% | 10.2% | |||
| 70Δ | 16.69 | 491.5% | 10.2% | |||
| 75Δ | 6.87 | 335.0% | 11.6% | |||
| 80Δ | 6.61 | 285.7% | 8.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.29
- IV
- 257.7%
- B/E move
- 22.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.72
- IV
- 224.3%
- B/E move
- 17.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.21
- IV
- 382.1%
- B/E move
- 19.7%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.61
- IV
- 347.7%
- B/E move
- 16.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.01
- IV
- 313.7%
- B/E move
- 12.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.74
- IV
- 319.6%
- B/E move
- 10.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.47
- IV
- 377.8%
- B/E move
- 10.2%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.69
- IV
- 491.5%
- B/E move
- 10.2%
75Δ
- Pseudo strike
- 6.87
- IV
- 335.0%
- B/E move
- 11.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 6.61
- IV
- 285.7%
- B/E move
- 8.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 168.98% | |
| 132.29% | |
| 210.48% | |
| 143.55% | |
| 160.96% | |
| 157.39% | |
| 222.25% | |
| 253.06% | |
| 186.57% |
Biotechnology
OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting…
More →ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The…
More →ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San…
More →ORKA
Oruka Therapeutics, Inc. is a biotechnology company.
More →ORMP
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or…
More →OTLK
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company…
More →